As sales of Merck & Co.’s immuno-oncology heavy hitter Keytruda soared 66% in the fourth quarter to $2.15 billion, surpassing Wall Street’s expectations they were knocked because analysts want to know ‘what’s next”?
Pharma is obsessed with fighting and winning and dominating even if it means making bad business decisions.
The wisdom of setting business goals—always striving for bigger and better—is so established within pharma that it seems like the only thing left to debate is whether the goals are ambitious enough.
Pharma, which used to cite the high cost of research, now say rebates within supply chain drive up prices.
Pharma says they don’t actually benefit much from list-price increases and that their net prices are suffering, because they are paying bigger rebates to pharmacy-benefit managers that negotiate prices in secret with their clients, such as employers and labor unions.
Drugmakers’ price increases are unrelated to the rebates, according to research commissioned by the Pharmaceutical Care Management Association, a trade group for PBMs.